Statin therapy in patients with chronic kidney disease: to use or not to use.
Dyslipdemia is a common complication of chronic kidney disease (CKD) and contributes to high cardiovascular morbidity and mortality of CKD patients. Experimental studies have demonstrated that lipids induce glomerular and tubulointerstitial injury and that lipid-lowering treatments ameliorate renal injury. Therapy with statins not only has the potential to lower cardiovascular morbidity and mortality in patients with CKD but also to slow progression of renal disease. Whereas the guidelines for treatment of hyperlipidaemia in nonrenal patients are based on prospective, randomized, placebo-controlled mega-trials, such data are not available for CKD patients. This review outlines the limited information currently available on the effect of statins among patients with CKD and summarizes the ongoing randomized trials designed to address this question.
Steinmetz
O M
OM
Department of Medicine, Division of Nephrology, University Hospital of Hamburg Eppendorf, Hamburg, Germany.
Panzer
U
U
Stahl
R A K
RA
Wenzel
U O
UO
D002784:Cholesterol / Q000096:biosynthesis; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000150:complications; D007674:Kidney Diseases / Q000150:complications / Q000188:drug therapy*; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy; D016030:Kidney Transplantation; D011507:Proteinuria / Q000150:complications; D016896:Treatment Outcome
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002784:Cholesterol